BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8669848)

  • 1. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
    Canobbio L; Cannata D; Miglietta L; Boccardo F
    Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
    Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
    Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
    Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
    Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatuline and tamoxifen in postmenopausal breast cancer patients.
    Canobbio L; Cannata D; Miglietta L; Boccardo F
    Ann N Y Acad Sci; 1993 Nov; 698():362-6. PubMed ID: 8279776
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer.
    Corsello SM; Rota CA; Putignano P; Della Casa S; Barnabei A; Migneco MG; Vangeli V; Barini A; Mandalà M; Barone C; Barbarino A
    Eur J Endocrinol; 1998 Sep; 139(3):309-13. PubMed ID: 9758441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis.
    Dolan JT; Miltenburg DM; Granchi TS; Miller CC; Brunicardi FC
    Ann Surg Oncol; 2001 Apr; 8(3):227-33. PubMed ID: 11314939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
    Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
    Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.
    Löfgren L; Wallberg B; Wilking N; Fornander T; Rutqvist LE; Carlström K; von Schoultz B; von Schoultz E
    Med Oncol; 2004; 21(4):309-18. PubMed ID: 15579914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.
    Helle SI; Mietlowski W; Guastalla JP; Szakolczai I; Bajetta E; Sommer H; Baltali E; Pinter T; Csepreghy M; Ottestad L; Boni C; Bryce C; Klijn JG; Lønning PE
    Eur J Cancer; 2005 Mar; 41(5):694-701. PubMed ID: 15763644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.
    Mansky PJ; Liewehr DJ; Steinberg SM; Chrousos GP; Avila NA; Long L; Bernstein D; Mackall CL; Hawkins DS; Helman LJ
    J Pediatr Hematol Oncol; 2002; 24(6):440-6. PubMed ID: 12218590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
    Figg WD; Thibault A; Cooper MR; Reid R; Headlee D; Dawson N; Kohler DR; Reed E; Sartor O
    Cancer; 1995 Apr; 75(8):2159-64. PubMed ID: 7535186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
    Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
    Ellmén J; Hakulinen P; Partanen A; Hayes DF
    Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.